← Back to Search

PET/CT Scans for Neuroendocrine Cancer

Phase 2

Recruiting

Led By Jonathan Abele

Research Sponsored by University of Alberta

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age greater or equal to 40

At least two abnormal 68Ga-HA-DOTATATE positive lesions suspected to represent neuroendocrine tumor (at least two lesions with SUVmax > SUV mean liver)

Must not have

Less than 40 years old

Weight > 225 kg (weight limitation of PET/CT scanner)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months after completion of the 68ga-ha-dotatate, 18f-fdg, and investigational 18f-dopa pet/ct scans

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing three different ways to detect neuroendocrine tumors, to see which is most effective.

Who is the study for?

This trial is for adults aged 40 or older with a confirmed diagnosis of neuroendocrine tumors, including various types such as gastrointestinal, pancreatic, pulmonary NETs and others. Participants must have at least two abnormal lesions that are positive on a specific PET/CT scan. It's not suitable for those over 225 kg, with serious illnesses affecting the study outcome, previous allergic reactions to the imaging drug used in the trial (18F-DOPA), pregnant or breastfeeding women, or those unable to undergo scans.

What is being tested?

The study compares three different PET/CT imaging agents—68Ga-HA-DOTATATE, 18F-DOPA with furosemide, and 18F-FDG—to see which one better detects metastatic neuroendocrine tumors on a lesion-by-lesion basis. The goal is also to understand if differences in tumor detection correlate with disease progression.

What are the potential side effects?

Potential side effects from the interventions may include allergic reactions to the imaging drugs used during PET/CT scans. However, detailed side effect profiles are not provided; participants should discuss possible risks with their physician.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 40 years old or older.

Select...

I have at least two lesions suspected to be a neuroendocrine tumor.

Select...

I have a confirmed diagnosis of a neuroendocrine tumor.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am under 40 years old.

Select...

I weigh less than 225 kg.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ within 1 year after completion of both 18f-dopa and 18f-fdg pet/ct scans

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~within 1 year after completion of both 18f-dopa and 18f-fdg pet/ct scans

This trial's timeline: 3 weeks for screening, Varies for treatment, and within 1 year after completion of both 18f-dopa and 18f-fdg pet/ct scans for reporting.